Extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving quetiapine and paroxetine

Pharmacotherapy

Volumn 24, Issue 7 I, 2004, Pages 923-925

  Bhanji, Nadeem H ^a,b   Margolese, Howard C ^a,b  

^a Allan Memorial Institute   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antipsychotic agents; Extrapyramidal symptoms; Nizatidine; Paroxetine; Psychotic disorders; Quetiapine; Schizophrenia; Weight control

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; PAROXETINE; QUETIAPINE;

ADOLESCENT; AKATHISIA; ARTICLE; BODY MASS; CASE REPORT; CLINICAL FEATURE; DELIRIUM; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; PARKINSONISM; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; BASAL GANGLIA DISEASES; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; NIZATIDINE; PAROXETINE;

EID: 3042701133     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.9.923.36096     Document Type: Article

References (21)

1. Guthrie SK. Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health-Syst Pharm 2002;59(suppl 5):S19-24.
2. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000;61:252-60.
3. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002;63(suppl 9):25-9.
4. 2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000;48:167-8.
5. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:81-5.
6. Stoa-Birketvedt G, Paus PN, Ganss R, Ingebretsen OC, Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int J Obes Relat Metab Disord 1998;22:1041-5.
7. Aronee LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001;62(suppl 23):13-22.
8. Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002;17:145-60.
9. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale (ESRS). Can J Neurol Sci 1980;7:233-4.
10. Sakata T, Yoshimatsu H, Kurokawa M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 1997;13:403-11.
11. 1) affects food intake in rats. J Nutr 1994;124:1029-36.
12. Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects. Br Med J 1993;306:1091-3.
13. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001;31:1-10.
14. Canadian Medical Association. Nizatidine drug information, Lexi-Drug online drug information. Available from http://www.cma.ca/cma/lexidrug/ displayMonograph.do?drugId=132473. Accessed March 10, 2004.
15. Itoh H, Nagano T, Takeyama M. Effect of nizatidine on paracetamol and its metabolites in human plasma. J Pharm Pharmacol 2002;54:869-73.
16. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22.
17. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. Psychopharmacol Bull 2003;37(suppl 1):29-41.
18. Atkinson GA, Hellewell JSE, Raniwalla J. Extrapyramidal symptom and tolerability profile of Seroquel (quetiapine): an overview of phase II/III placebo controlled trials [abstr]. Eur Neuropsychopharmacol 1997;7(suppl 2):S224.
19. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine [letter]. Am J Psychiatry 1999;156:796-7.
20. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57(10): 449-54.
21. Galynker II, Tendler DS. Nizatidine-induced delirium in a nonagenarian [Ietter]. J Clin Psychiatry 1997;58:327.